Michael Niederman, MD
Pulmonary Disease · New York, NYNPI 1073675005
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (42.9%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. 17 manufacturers reported payments, led by Merck at 57.9% of the total. Reporting peaked in 2019 at $58,070 and has fallen 96.3% since, to $2,125 in 2025. Among pulmonary disease clinicians in NY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 126 payments — averaging $1396.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Merck$102K
- Fisher Scientific Company L.L.C.$21K
- Dompe US, Inc.$11K
- Gilead$10K
- Pfizer$8K
- Diasorin Molecular LLC$8K
- plus $17K from 11 others
Across 31 payments — averaging $5624.05 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Boehringer Ingelheim$100K
- Shionogi Inc$36K
- Boehringer Ingelheim Pharma GmbH & Co.kg$18K
- Amgen$17K
- Merck$2K
- Boehringer Ingelheim International GmbH$1K
What the payments were for
- Consulting fees$70,10640%
- Speaking & faculty fees$75,49143%
- Travel & lodging$28,71616%
- Food & beverage$1,6311%
- Education$370%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Merck | 64 | $101,835 |
| Fisher Scientific Company L.L.C. | 18 | $20,834 |
| Dompe US, Inc. | 5 | $11,050 |
| Gilead | 6 | $10,394 |
| Pfizer | 7 | $7,771 |
| Diasorin Molecular LLC | 1 | $7,500 |
| GSK | 4 | $6,022 |
| Bayer | 3 | $5,750 |
| Shionogi Inc | 1 | $1,800 |
| Astrazeneca UK Limited | 8 | $1,483 |
| Eli Lilly | 1 | $1,050 |
| Abbott | 2 | $169 |
| AstraZeneca | 2 | $100 |
| Paratek Pharmaceuticals, Inc. | 1 | $95 |
| Accelerate Diagnostics Inc. | 1 | $78 |
| Phadia US Inc. | 1 | $30 |
| Nabriva Therapeutics, PLC | 1 | $21 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Procalcitonin$18,632
- Veklury$10,350
- ZERBAXA$8,197
- RECARBRIO$8,197
- PNEUMOVAX 23$6,226
- BRAHMS PCT KRYPTOR$2,000
- Fetroja$1,800
- TALTZ$1,050
How this compares
$175,981 in reported general payments places this provider in the 95th percentile of 1,115 pulmonary disease providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 165 | $126,125 |
| Dupixent SyringeDupilumab | 13 | $49,699 |
| Breo ElliptaFluticasone/Vilanterol | 89 | $40,237 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 60 | $30,903 |
| Spiriva HandihalerTiotropium Bromide | 11 | $17,226 |
| SymbicortBudesonide/Formoterol Fumarate | 66 | $16,925 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 18 | $10,508 |
| Advair HfaFluticasone Propion/Salmeterol | 23 | $10,416 |
| Advair DiskusFluticasone Propion/Salmeterol | 28 | $8,996 |
| Arnuity ElliptaFluticasone Furoate | 30 | $7,354 |
| DuleraMometasone/Formoterol | 22 | $7,249 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 63 | $7,214 |
| Incruse ElliptaUmeclidinium Bromide | 19 | $7,050 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 35 | $6,001 |
| Spiriva RespimatTiotropium Bromide | 11 | $5,709 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Arnuity Ellipta, Incruse Ellipta | $6,022 | $211,669363 claims |
| AstraZenecaSymbicort, Bevespi Aerosphere | $100 | $22,28879 claims |
| MerckDulera | $101,835 | $7,24922 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,115 pulmonary disease providers in New York.
Other pulmonary disease in New York
- Charles PowellNew York$654K
- Bisher AkilNew York$480K
- Sonali SethiNew York$388K
- Johnathan RaskinNew York$338K
- Monica KraftNew York$247K
- Jamie BessichNew York$226K
- Ronald CrystalNew York$213K
- Wilfredo TalaveraNew York$145K
- Josanna Rodriguez-LopezNew York$128K
- Kenneth BergerNew York$126K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.